Articles
21 November 2022
Vol. 14 No. 4 (2022)
Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
1407
Views
355
Downloads
20
HTML
Authors
Etanercept is approved for continuous or intermittent use and flexible dosing in plaque psoriasis (PsO). The objectives of this study were to investigate real-world treatment patterns with etanercept in Greek adults with moderate-to-severe PsO. This non-interventional multicenter study included a retrospective-to-prospective (RP) cohort, previously treated with etanercept for ≥24 months and followed for an additional 6 months, and a biologic-naïve, prospective-only (PO) cohort, followed for 6 months after treatment initiation. Parameters assessed included Psoriasis Area and Severity Index (PASI), percentage of body surface area (BSA) affected, Dermatology Life Quality Index (DLQI), and adverse events (AEs). This study enrolled 123 patients (RP, n = 56; PO, n = 67), who mostly adhered to continuous treatment (RP, 68%; PO, 95%). The two cohorts had similar mean baseline-to-endpoint decreases in PASI (-9.5 vs -10.1) and BSA (-11.9 vs -12.3). The PO-CTP population had a mean DLQI baseline-to-endpoint score decrease of -5.8, which was statistically significant and clinically meaningful. Treatment-emergent AE rates were 58.9% (RP) versus 26.9% (PO). These real-world data suggest a similar effectiveness of continuous and intermittent etanercept treatment in Greek patients with PsO.
Altmetrics
Downloads
Download data is not yet available.
Citations
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50. DOI: https://doi.org/10.1016/j.jaad.2008.02.039
Park BS, Youn JI. Factors influencing psoriasis: an analysis based upon the extent of involvement and clinical type. J Dermatol 1998;25:97-102. DOI: https://doi.org/10.1111/j.1346-8138.1998.tb02357.x
European Medicines Agency. Enbrel. Summary of Product Characteristics 2020 Available from:
http://www.ema.europa.eu/docs/en_GB/ d o c u m e n t _ l i b r a r y / E PA R _ -
_Product_Information/human/000262/WC500027361.pdf. Last accessed: May 22, 2020.
Siegfried EC, Eichenfield LF, Paller AS, et al. Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol 2010;63:769-74. DOI: https://doi.org/10.1016/j.jaad.2009.10.046
Ortonne JP, Griffiths CEM, Daudén E, et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Exp Rev Derm 2008;3:657-65. DOI: https://doi.org/10.1586/17469872.3.6.657
Cassano N, Loconsole F, Miracapillo A, et al. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Talpharanta Plastic Study Group. Int J Immunopathol Pharmacol 2010;23:797-802. DOI: https://doi.org/10.1177/039463201002300314
Gordon KB, Gottlieb AB, Leonardi CL, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006;17:9-17. DOI: https://doi.org/10.1080/09546630500472838
Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007;56:598-603. DOI: https://doi.org/10.1016/j.jaad.2006.09.002
Ortonne JP, Taieb A, Ormerod AD, et al. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol 2009;161:1190-5. DOI: https://doi.org/10.1111/j.1365-2133.2009.09238.x
Griffiths CE, Luger TA, Brault Y, et al. Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study. J Eur Acad Dermatol Venereol 2015;29:468-73. DOI: https://doi.org/10.1111/jdv.12585
Dauden E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009;23:1374-82. DOI: https://doi.org/10.1111/j.1468-3083.2009.03321.x
Gelfand JM, Kimball AB, Mostow EN, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008;11:400-7. DOI: https://doi.org/10.1111/j.1524-4733.2007.00251.x
Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol 2010;9:928-37.
Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009;23:896-904. DOI: https://doi.org/10.1111/j.1468-3083.2009.03211.x
Ruiz-Villaverde R, Galan-Gutierrez M, Barabash-Neila R, et al. Efficacy and cost of etanercept in long-term psoriasis: Rational use in clinical practice. J Dermatolog Treat 2016;27:37-42. DOI: https://doi.org/10.3109/09546634.2015.1054776
Moreno-Ramirez D, Ojeda-Vila T, Ferrandiz L. Disease control for patients with psoriasis receiving continuous versus interrupted therapy with adalimumab or etanercept: a clinical practice study. Am J Clin Dermatol 2014;15:543-9. DOI: https://doi.org/10.1007/s40257-014-0095-3
Barrera MV, Habicheyn S, Mendiola MV, et al. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 2008;18:683-7.
Luger T, Schopf RE, Schwanke A, et al. An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis. J Eur Acad Dermatol Venereol 2016;30:1730-41. DOI: https://doi.org/10.1111/jdv.13673
Segaert S, Ghislain PD, Boone C. An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium). J Dermatolog Treat 2016;27:103-9. DOI: https://doi.org/10.3109/09546634.2015.1055228
Puig L, Camacho Martínez FM, Gimeno Carpio E, et al. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up. Dermatology 2012;225:220-30. DOI: https://doi.org/10.1159/000343605
Rigopoulos D, Gregoriou S, Katrinaki A, et al. Characteristics of psoriasis in Greece: an epidemiological study of a population in a sunny Mediterranean climate. Eur J Dermatol 2010;20:189-95 DOI: https://doi.org/10.1684/ejd.2010.0869
Supporting Agencies
PfizerHow to Cite
Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece. (2022). Dermatology Reports, 14(4). https://doi.org/10.4081/dr.2022.9265
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
